During the past decade, Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 4 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 3 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie" #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "Vivoryon Therapeutics N.V." with 2 trials sponsored, "Actelion" with 1 trials sponsored, "Autonomic Technologies, Inc." with 1 trials sponsored and "Boehringer Ingelheim" with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie" #1 collaborator was "Amsterdam UMC, location VUmc" with 2 trials as a collaborator, "Advancell - Advanced In Vitro Cell Technologies, S.A." with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "European Commission" with 1 trials as a collaborator and "Genzyme, a Sanofi Company" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie" are "Multiple Sclerosis, Relapsing-Remitting" (4 trials), "Multiple Sclerosis" (3 trials), "Alzheimer Disease" (2 trials), "Alzheimer's Disease" (2 trials) and "Autoimmune Encephalitis" (1 trials). Many other conditions were trialed in "Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie" are "Drug" (18 trials), "Other" (3 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Ocrelizumab" (3 trials), "Gantenerumab" (2 trials), "Albumin (Human) 25%, United States Pharmacopeia (USP)" (1 trials) and "Alemtuzumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie" are 23 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie". 1 are not yet recruiting, 6 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".